

Daley, Denise <Denise.Daley@health.wa.gov.au> 23 May 2018 at 13:09

To: David Paterson <david.antibiotics@gmail.com>

Cc: Geoffrey Coombs <geoff@asainc.net.au>

Hi David

The AGAR reports can be found at www.agargroup.org.au under the surveys tab. Please note that AGAR must be acknowledged if any data is used in presentations or publications.

I have attached the AESOP 2016 report here.

To answer your questions: For the 2016 study

1. The number of enterococcus episodes

Please provide by species

Total Enterococcal episodes – 1,058

E. faecalis – 595

E. faecium – 413

E. casseliflavus – 25

E. gallinarum – 11

E. avium – 8

E. raffinosus – 3

E. hirae - 3

2. the proportion associated with endocarditis

Principle clinical manifestation was known for 1,004 episodes of bacteraemia

L-sided endocarditis – 72 (7.2%)

R-sided endocarditis – 11 (1.1%)

3. Cases of VRE

please include overall mortality we used in the report

30 day mortality was known for 917 of 1,058 episodes

Overall mortality – 177 (19.3%)

All E. faecium mortality – 103/379 (27.2%)

Vanc resistant E. faecium mortality – 53 /186 (28.5%)

All E. faecalis mortality – 64/497 (12.9%)

Vanc resistant E. faecalis mortality – 0/2 (0%)

Regards,

Denise Daley, MASM
AGAR Scientific Officer
www.agargroup.org.au
ASA Secretary
www.asainc.net.au

Geoffrey Coombs [<mailto:geoffasa@gmail.com>] **Wednesday, 23 May 2018 12:13 PM**

To: David Paterson
Cc: Geoffrey Coombs; Daley, Denise
Subject: Re: AESOP

Hi David

Requests 1,2 and 5 - not a problem

Unfortunately we don't collect the info required for requests 3 and 4

Denise, using the 2016 data, could you please let David know

1. The number of enterococcus episodes

Please provide by species

2. the proportion associated with endocarditis

3. Cases of VRE

please include overall mortality we used in the report

Could you also email David the final report as on the AGAR website

Thank you

Geoff

David Paterson <david.antibiotics@gmail.com> **23 May 2018 at 08:52**

To: Geoffrey Coombs <geoff@asainc.net.au>

Many thanks Geoff.

If I can boil it down to four or five simple questions:

1. How many cases of Enterococcus bloodstream infection do we see annually in Australia (AGAR participating sites)?
2. What proportion of cases are associated with endocarditis?
3. What are the overall comparative mortality rates for patients treated with ampicillin alone, ampicillin plus gentamicin, and ampicillin plus ceftriaxone?
4. What are these mortality rates by antibiotic, purely for endocarditis?

5. How many cases of VRE BSI do we see each year and what is its mortality?

The purpose of collecting this data is to provide preliminary data for sample size calculation for a pragmatic RCT on combination therapy versus monotherapy for enterococcal BSI.

I hope that AGAR can help!

Best wishes

David

On Wed, May 23, 2018 at 8:15 AM, Geoffrey Coombs <geoff@asainc.net.au> wrote:

Hi David

Also good to see you during ECCMID

Regarding your AGAR data request...

This can be difficult to accommodate - mainly due to the data management and governance arrangements between the Commission and ASA (who own AGAR) - but also will depend on current AGAR projects that are being performed

If you could please email me what data you are seeking and I will raise at the next AGAR Executive Meeting

Kind regards

Geoff

Professor Geoffrey Coombs

AGAR Chair

ASA President-Elect

From: David Paterson [<mailto:david.antibiotics@gmail.com>] Thursday, 10 May 2018 12:35 PM

To: Coombs, Geoffrey; Geoff Coombs

Cc: John Turnidge

Subject: AESOP

Hi Geoff

Good to see you (ultrabriefly!) in Madrid.

I was wondering what the process is to access AESOP data (not the organisms). I am keen to undertake a followup to the MERINO trial on enterococcal BSI and need some clinical data to generate hypotheses (or support mine!).

Are you able to help me with this?

Thanks so much

Best wishes

David